NVCR News and Press, NovoCure Limited From 03/23/22

An independent data monitoring has recommended that a phase 3 trial of Novocure's (NASDAQ:NVCR) Tumor Treating Fields (TTFs) for ovarian cancer should continue following an interim analysis. The analysis showed that an increase in sample size is not necessary and the committee recommended tha...

Pre-specified interim analysis concluded that the INNOVATE-3 study should proceed to final analysis as planned Novocure (NASDAQ: NVCR) today announced the results of a pre-specified interim analysis for the phase 3 pivotal INNOVATE-3 study evaluating the safety and efficacy ...

One positive spin we can put on the “great growth stock bear market of 2022” – which, let’s face it, is what we are dealing with so far this year – is the value being created for future portfolio returns. We have seen indiscriminate selling in many high-grow...

March is the month when most of us like to see some green. But in addition to the greenery in the great outdoors (and on St. Patrick's Day), investors would also like to see some green in their portfolios. Three Motley Fool contributors took at look at some biotech stocks that could mak...

NovoCure's revenue growth has slowed down in recent quarters. COVID-19 is having an impact, but Optune in GBM is also in a more mature stage with 35% market penetration in existing markets. Longer term, there are significant growth opportunities in the GBM market, driven by device...

Professor Palti is the inventor of Tumor Treating Fields, electric fields that disrupt cancer cell division The Israel Prize is regarded as the State of Israel’s highest cultural honor Novocure (NASDAQ: NVCR) today announced that Yoram Palti, Novocure’s...

Todd Longsworth’s work was foundational to the growth of Novocure in becoming a global oncology company Barak Ben Arye has been appointed to General Counsel, effective April 1 Novocure (NASDAQ: NVCR) today announced that Todd Longsworth, General Counsel, has r...

Image source: The Motley Fool. Novocure (NASDAQ: NVCR) Q4 2021 Earnings Call Feb 24, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Novocure (NVCR) Q4 2021 Earnings Call Transcript

NovoCure Limited (NVCR) Q4 2021 Earnings Conference Call February 24, 2022 8:00 AM ET Company Participants Ingrid Goldberg – Vice President of Finance and Investor Relations Bill Doyle – Executive Chairman Asaf Danziger – Chief Executive Officer Ashley Cordova – Ch...

The following slide deck was published by NovoCure Limited in conjunction with their 2021 Q4 earnings call. For further details see: NovoCure Limited 2021 Q4 - Results - Earnings Call Presentation